Clinical Trial Update: Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination including iparomlimab and tuvoraleimab with bevacizumab, nab-paclitaxel, and carboplatin as first- or second-lin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Melanoma
• Mucosal Melanoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Tuvoraleimab (tuvoraleimab)
• iparomlimab

Snippet

Sponsor: Fudan University | Conditions: Acral Melanoma, Mucosal Melanoma | Phase 2 | Status: NOT_YET_RECRUITING